MacroGenics Inc
NASDAQ:MGNX
MacroGenics Inc
Revenue
MacroGenics Inc
Revenue Peer Comparison
Competitive Revenue Analysis
Latest Figures & CAGR of Competitors
Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
MacroGenics Inc
NASDAQ:MGNX
|
Revenue
$58.7m
|
CAGR 3-Years
-18%
|
CAGR 5-Years
0%
|
CAGR 10-Years
0%
|
|
Abbvie Inc
NYSE:ABBV
|
Revenue
$54.3B
|
CAGR 3-Years
6%
|
CAGR 5-Years
11%
|
CAGR 10-Years
11%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Revenue
$27.5B
|
CAGR 3-Years
2%
|
CAGR 5-Years
4%
|
CAGR 10-Years
7%
|
|
Amgen Inc
NASDAQ:AMGN
|
Revenue
$28.2B
|
CAGR 3-Years
4%
|
CAGR 5-Years
3%
|
CAGR 10-Years
4%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Revenue
$9.9B
|
CAGR 3-Years
17%
|
CAGR 5-Years
26%
|
CAGR 10-Years
23%
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Revenue
$13.1B
|
CAGR 3-Years
16%
|
CAGR 5-Years
14%
|
CAGR 10-Years
20%
|
MacroGenics Inc
Revenue Breakdown
Breakdown by Geography
MacroGenics Inc
Breakdown by Segments
MacroGenics Inc
Total Revenue:
58.7m
USD
|
Revenue From Collaborative Agreements:
29m
USD
|
Product:
17.9m
USD
|
Contract Manufacturing:
9.8m
USD
|
Revenue From Government Agreements:
1.6m
USD
|
Revenuefromroyalityagreementsmember:
431k
USD
|
See Also
What is MacroGenics Inc's Revenue?
Revenue
58.7m
USD
Based on the financial report for Dec 31, 2023, MacroGenics Inc's Revenue amounts to 58.7m USD.
What is MacroGenics Inc's Revenue growth rate?
Revenue CAGR 10Y
0%
Over the last year, the Revenue growth was -61%. The average annual Revenue growth rates for MacroGenics Inc have been -18% over the past three years .